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42 Clinical characteristics of infants diagnosed through cystic
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CF NBS in Poland started in 2006, the Warsaw CF Centre being responsible for
25% of the population (over 100,000 births a year). The screening protocol is based
on IRT/DNA analysis, covering the 15 most common mutations as well as over 300
of the less common using sequencing technology.
Among the 43 infants disgnosed were 10 with meconium ileus – MI (only 2 did
not have increased IRT values).
The average age of diagnosis was 46.6 days. Both mutations were known in 38
out of 43 infants. The most common were F508del homozygotes (44, 2%) and
F508del heterozygotes (32.6%). In 5 patients only 1 mutation was found. Among
MI infants 60% were F508del homozygotes. The average sweat test values were
68.9%. In 2 children sweat test values were lower than 40mmol/l. There were
8 children who at the time of diagnosis were symptom free, 5 presented respiratory
symptoms, 5 both: respiratory and gastrointestinal (GI), and 25 only GI syndroms
(MI, steatorrhea, hiperbilirubinemia, worse somatic development). 30% of the
patients were pancreatic sufﬁcient. There were no radiological changes at x-ray
on diagnosis. In 4 children Pseudomonas aeruginosa colonisation was conﬁrmed
in the ﬁrst year of life.
Conclusions:
1. In most of the CF infants GI symptoms were observed at the time of diagnosis
2. Most of hte MI infants had increased IRT values and were detected through the
normal screening protocol
3. In screened newborns positive sweat test should be established at 30mmol/l
4. A larger spectrum of mutations enables diagnosis of CF even in infants with
normal sweat tests.
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Early diagnosis and treatment can improve survival in Cystic Fibrosis (CF).
Aim: to determine if certain risk factors (RF) may impact clinical outcomes.
Methods: Retrospective study of clinical ﬁles of CF patients (age range 0−24 years)
followed up between 1999–2009 in a Children’s Hospital. RF: late follow up after
diagnosis (LFD), poor socioeconomic status (PSS), malnutrition at diagnosis (MD),
del F508 homozygous(HDF), frequent pulmonary exacerbations(PE), early Paer
colonization(EPC), associated conditions(AC) were correlated with clinical scores
quantiﬁed at the time of ﬁle analysis. Funding for CF care since 2004 was taken into
account in evaluation. Study population was divided in group A (25/38-diagnosis
under the age of 1 year) and group B (5/38-after the age of 1 year), excluding
meconium ileus (MI) patients.
Results: 10 patients died (70% before 2004, mean age at death 1.1 year).21%
presented with MI and underwent surgery. Age when started follow up differed
between groups (0.38 months vs.4.57 years)which impacted on recurrence of PE
(53% vs 83%) (p< 0.001). 81% patients were genotyped; 57% of the 28 currently
followed up were HDF. 35% (10/28)patients still had malnutrition at evaluation;
this correlated in 35% (8/28) with PSS and negatively impacted on Schwachmann
scores. Early CFLD (4/38), ABPA (2/38) and reintervention for complicated MI
(6/8) inﬂuenced the outcomes. 85% patients had EPC. PE were more frequent in
patients who associated PSS, MD, AC. Lung function was poorer over the study
period in the late followed up patients with more RF.
Conclusion: Beyond early age at diagnosis and high standards of care-goals that
have to be achieved, there are RF that may be inﬂuenced in order to improve the
outlook of CF patients.
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Great strides have been made in expansion of the CF newborn screening programs
in the USA, to include all states by the year 2010. Three different protocols are
currently in use throughout the states: IRT/IRT, IRT/DNA, and IRT/IRT/DNA. This
study presents a comprehensive cost analysis and, for the ﬁrst time, includes costs
related to genetic counseling (GC), and collection of the 2nd dried blood specimen
(2nd DBS) required in both the IRT/IRT and IRT/IRT/DNA screening algorithms.
Other costs being included relate to differences in the numbers of sweat test referrals
observed with each protocol and complete laboratory costs (equipment, reagents,
courier services, space, information systems, overhead, and maintenance). With
information obtained from a sample of states using each protocol, we created a
model for cost comparison that included all of these elements. Preliminary analysis
of cost data collected at the University of Kentucky related to the 2nd DBS for
the IRT/IRT protocol demonstrated a cost increase of at least $0.16 per newborn.
Analysis of GC cost data from Wisconsin, utilizing IRT/DNA, revealed an increase
of $0.04 per newborn. Thus, our results demonstrate that GC is not a substantial
cost barrier to implementation of IRT/DNA and is less than the 2nd DBS expenses.
In conclusion, our ﬁndings suggest that the expenses for obtaining the 2nd DBS
should be taken into account in regions using IRT/IRT and may be a higher system-
wide cost than that for DNA analyses. Calculations related to IRT/IRT/DNA are
still underway, as are further analyses to compare the cost-beneﬁts of each protocol.
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Since the CFTR gene cloning, more than 1500 genetic alterations have been
so far described; most of them are disease-causing mutations. We present here
two cases which have 1524+6insC+12G>A mutations in intron 9. In sequence
database, several different regions were determined for the homology with the
CFTR exon 9 and its intronic boundaries. The comparison of homologous se-
quences are 95−96% similar to each other, inducing the interference of our
target sequence with other homologous sequences in human genome. Sequence
alignment analysis reveals that ﬁve registered mutations in CF mutation database,
http://www.genet.sickkids.on.ca/cftr, may be due to this similarity and prevent the
correct screening of mutations. For this reason, we conclude from this statement
that there are some pseudomutations resulting from the identity of CFTR exon 9
and its ﬂanking regions with similar-related sequences in the human genome. Using
speciﬁc PCR primers or high annealing temperature, we can amplify speciﬁcally the
CFTR exon 9 region, and not the pseudogene sequences. We suggest that patients
carring mutation in this region should be re-examined with our speciﬁc technique.
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